(2-Aminophenyl)-(4-ethylphenyl)methanol | 841236-84-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-Aminophenyl)-(4-ethylphenyl)methanol
• CAS: 841236-84-8
• 化学式: C₁₅H₁₇NO
• mdl: MFCD20216871
• 分子量: 227.306
• InChiKey: IBBSCGFXCRUGIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-Aminophenyl)-(4-ethylphenyl)methanol 在 三乙基硅烷 、 三氟化硼乙醚 、 氯化铵 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 2-(4-ethylbenzyl)-N-(beta-D-glucopyranosyl)aniline
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042
• 作为产物：
  描述：

  对溴乙基苯 在 正丁基锂 、 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (2-Aminophenyl)-(4-ethylphenyl)methanol
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042

文献信息

• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20070060545A1

  公开（公告）日：2007-03-15

  A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH 2 — group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B分别为（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，或（3）环A为可选取代的不饱和融合杂双环，其中—NR—基团和—CH2—基团均位于不饱和融合杂双环的同一环上，环B为可选取代的单环不饱和杂环、可选取代的不饱和融合杂双环或可选取代的苯环；R为氢原子、低碳基、低烷酰基或低烷氧羰基基团，或其药学上可接受的盐或前药。
• NOVEL COMPOUNDS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1654269B1

  公开（公告）日：2014-10-15
• US7521430B2
  申请人：——

  公开号：US7521430B2

  公开（公告）日：2009-04-21
• N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors
  作者：Yasuo Yamamoto、Eiji Kawanishi、Yuichi Koga、Shigeki Sakamaki、Toshiaki Sakamoto、Kiichiro Ueta、Yasuaki Matsushita、Chiaki Kuriyama、Minoru Tsuda-Tsukimoto、Sumihiro Nomura

  DOI：10.1016/j.bmcl.2013.08.042

  日期：2013.10

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.